Overview

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Status:
Recruiting
Trial end date:
2024-05-27
Target enrollment:
Participant gender:
Summary
Phase 1b clinical study to evaluate the PK of oral AZD4547 in Chinese patients and RP2D. Phase 2 study to evaluate the efficacy of AZD4547 in urothelial carcinoma patients with FGFR2/3 gene alterations.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Abbisko Therapeutics Co, Ltd